<DOC>
	<DOC>NCT01043887</DOC>
	<brief_summary>This study will evaluate the pharmacokinetics of ridaforolimus including the area under the concentration-time curve (AUC[0-infinity]) and maximum concentration (Cmax) after administration of a single dose of ridaforolimus in patients with moderate hepatic insufficiency and healthy matched control subjects.</brief_summary>
	<brief_title>Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046)</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Hepatic Patients: Female patient is of nonchild bearing potential Apart from hepatic insufficiency with features of cirrhosis, patient is otherwise in good health Patient has a diagnosis of chronic stable hepatic insufficiency with features of cirrhosis Healthy Subjects: Female subject is of nonchildbearing potential Subject is in good health Hepatic Patients and Healthy Subjects: Works a night shift and is not able to avoid night shift work during the study Has a history of stroke, seizure or major neurological disease Has a history of cancer Is unable to refrain from or anticipates the use of any prescription or nonprescription drugs during the study Consumes excessive amounts of alcohol or caffeine Has had major surgery, donated blood or participated in another investigational study in the past 4 weeks</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Hepatic Insufficiency</keyword>
</DOC>